Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
Primary Purpose
Lipodystrophy
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Venus Versa
Glycerine gel
Sponsored by
About this trial
This is an interventional treatment trial for Lipodystrophy focused on measuring body fat
Eligibility Criteria
Inclusion Criteria:
- Body mass index (BMI) score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
- Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.
- For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, Intra Uterine Device (IUD), contraceptive implant, barrier methods with spermicide, or abstinence).
Exclusion Criteria:
- Pregnant or planning to become pregnant, having given birth less than 9 months ago, and/or breastfeeding.
- Having any active electrical implant anywhere in the body,
- Having a permanent implant in the treated areas
- Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
- Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 2 years of treatment
- Having or undergoing any form of cancer
- Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
- Having a anticoagulative or thromboembolic condition or taking anticoagulation medications
- History of immunosuppression/immune deficiency disorders
- Suffering from hormonal imbalance which may affect weight or cellulite
- History of significant lymphatic drainage problems.
- History of keloid scarring or of abnormal wound healing.
- History of being especially prone to bruising.
- History of epidermal or dermal disorders
- Use of isotretinoin within 6 months
- Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.
- Participation in a study of another device or drug within 1 month prior to enrollment or during this study.
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Sites / Locations
- J Dermatology and Allergy
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Treatment Group
Control Group
Arm Description
Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
Outcomes
Primary Outcome Measures
Abdominal Circumference
Abdominal circumference measurement of the treated area at 1 month after the last treatment performed by controlled tape measurement
Secondary Outcome Measures
Subject Satisfaction With Treatment
Subject 5-point Likert Satisfaction Assessment Scale where 4 = Very satisfied; 3 = Satisfied; 2 = Having no opinion; 1 = Unsatisfied and 0 = Very unsatisfied.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02492997
Brief Title
Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
Official Title
Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
Study Type
Interventional
2. Study Status
Record Verification Date
November 2020
Overall Recruitment Status
Terminated
Why Stopped
Trial was terminated early due to slow enrollment.
Study Start Date
May 14, 2015 (Actual)
Primary Completion Date
October 25, 2016 (Actual)
Study Completion Date
October 31, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Venus Concept
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The octipolar applicator is intended for circumference reduction treatment by reduction of adipose size and enhancement of collagen synthesis as the result thermal and non-thermal collagen stimulation. This trial is intended to evaluate the effect of radio frequency (RF) and pulsed electromagnetic fields (PEMF) treatment on circumference reduction.
Detailed Description
This is a multi-site, prospective, controlled, randomized, double blinded clinical trial. This study is designed to evaluate the safety and efficacy of a series of treatments using the Venus Versa Octipolar applicator. Up to 60 healthy subjects at 10 sites shall be recruited by the investigator from within the investigator's subject population. Subjects shall have abdomen circumference to reduce for the designated treatment area.
Each subject will undergo 6 treatments at an interval of one treatment per week for six consecutive weeks. There will be a one month follow up which will occur 4 weeks after the 6th treatment.
At the first treatment visit, the investigator will collect demographic and medical information and randomization will take place. Subjects have an equal opportunity to be selected for the treatment or the control group.
The duration of the treatment session will be approximately 60 minutes. Expected immediate response includes temporary mild to moderate erythema and/or edema. Skin safety assessments will be conducted by the investigator after each treatment session and at the follow-up visit.
Photography will be conducted at baseline, the beginning of 4th & 6th treatment and at 1 month follow up visit. Subjects will be asked to complete a questionnaire after each treatment and at the one month follow up visit.
Circumference measurements will be conducted at base line, before each treatment and at follow up visit. The treatment will be considered successful if the treated area circumference, reduces by at least 2.5 cm.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lipodystrophy
Keywords
body fat
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
44 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment Group
Arm Type
Experimental
Arm Description
Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
Arm Title
Control Group
Arm Type
Sham Comparator
Arm Description
Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
Intervention Type
Device
Intervention Name(s)
Venus Versa
Intervention Description
The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
Intervention Type
Other
Intervention Name(s)
Glycerine gel
Intervention Description
Gel used to protect the skin from the RF energy and to assist with energy distribution
Primary Outcome Measure Information:
Title
Abdominal Circumference
Description
Abdominal circumference measurement of the treated area at 1 month after the last treatment performed by controlled tape measurement
Time Frame
1 month post treatment series
Secondary Outcome Measure Information:
Title
Subject Satisfaction With Treatment
Description
Subject 5-point Likert Satisfaction Assessment Scale where 4 = Very satisfied; 3 = Satisfied; 2 = Having no opinion; 1 = Unsatisfied and 0 = Very unsatisfied.
Time Frame
1 month post treatment series
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Body mass index (BMI) score is greater than 18.5 and less than 29.9 - normal to overweight, but not obese.
Willingness to refrain from a change in diet/drinking/exercise/medication regimen for the entire course of the study.
For female of child bearing potential - using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, Intra Uterine Device (IUD), contraceptive implant, barrier methods with spermicide, or abstinence).
Exclusion Criteria:
Pregnant or planning to become pregnant, having given birth less than 9 months ago, and/or breastfeeding.
Having any active electrical implant anywhere in the body,
Having a permanent implant in the treated areas
Having received treatment with laser, RF or other devices in the treated areas within 6 months of treatment or during the study.
Having undergone a liposuction surgery or any contouring treatment in the areas intended for treatment within 2 years of treatment
Having or undergoing any form of cancer
Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders.
Having a anticoagulative or thromboembolic condition or taking anticoagulation medications
History of immunosuppression/immune deficiency disorders
Suffering from hormonal imbalance which may affect weight or cellulite
History of significant lymphatic drainage problems.
History of keloid scarring or of abnormal wound healing.
History of being especially prone to bruising.
History of epidermal or dermal disorders
Use of isotretinoin within 6 months
Significant change in diet or exercise regimen within a month of enrollment or during this study and/or weight loss or gain of 10 lbs (4.5 kgs) within 2 months of enrollment or during this study.
Participation in a study of another device or drug within 1 month prior to enrollment or during this study.
As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tracey L Mancuso
Organizational Affiliation
Venus Concept
Official's Role
Study Director
Facility Information:
Facility Name
J Dermatology and Allergy
City
Fort Lee
State/Province
New Jersey
ZIP/Postal Code
07024
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference
We'll reach out to this number within 24 hrs